Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Cabaletta Bio Inc is a biotechnology business based in the US. Cabaletta Bio shares (CABA) are listed on the NASDAQ and all prices are listed in US Dollars. Cabaletta Bio employs 56 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $1.15 |
|---|---|
| 52-week range | $0.90 - $14.95 |
| 50-day moving average | $1.29 |
| 200-day moving average | $5.34 |
| Wall St. target price | $12.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.84 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.15 from 2022-07-05
| 1 week (2022-06-29) | 10.05% |
|---|---|
| 1 month (2022-06-02) | -8.00% |
| 3 months (2022-04-05) | -44.71% |
| 6 months (2022-01-05) | -69.66% |
| 1 year (2021-07-06) | -85.63% |
|---|---|
| 2 years (2020-07-06) | -89.87% |
| 3 years (2019-07-02) | N/A |
| 5 years (2017-07-02) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -28.06% |
| Return on equity TTM | -47.17% |
| Profit margin | 0% |
| Book value | $3.68 |
| Market capitalisation | $30.7 million |
TTM: trailing 12 months
We're not expecting Cabaletta Bio to pay a dividend over the next 12 months.
Over the last 12 months, Cabaletta Bio's shares have ranged in value from as little as $0.9 up to $14.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cabaletta Bio's is 1.5299. This would suggest that Cabaletta Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cabaletta Bio, Inc. , a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.